Atactic disorder
MONDO:0100308A central nervous system disease that consists of gait impairment, unclear (“scanning”) speech, visual blurring due to nystagmus, hand incoordination, and tremor with movement.
Also known as: ataxic disorder, ataxia
148 clinical trials for this condition and its sub-types, 5 tagged with Atactic disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Atactic disorder
-
Cerebellar ataxia 40 trials · 144 incl. sub-types
1 sub-type
- Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types Sub-types →
-
Hereditary ataxia 2 trials · 119 incl. sub-types
20 sub-types
- Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types Sub-types →
- Spastic ataxia 1 trial · 2 incl. sub-types Sub-types →
- EAST syndrome 1 trial
- Hereditary episodic ataxia 0 trials · 1 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 7 1 trial
- Richards-Rundle syndrome 0 trials
- Ataxia with fasciculations 0 trials
- Ataxia-hypogonadism-choroidal dystrophy syndrome 0 trials
- Ataxia-tapetoretinal degeneration syndrome 0 trials
- Autosomal dominant sensory ataxia 1 0 trials
- Autosomal recessive ataxia due to PEX16 deficiency 0 trials
- Autosomal recessive ataxia due to PEX2 deficiency 0 trials
- Cataract-ataxia-deafness syndrome 0 trials
- Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome 0 trials
- Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome 0 trials
- Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome 0 trials
- Myoclonus-cerebellar ataxia-deafness syndrome 0 trials
- Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome 0 trials
- Spinocerebellar ataxia-dysmorphism syndrome 0 trials
- Tremor-ataxia-central hypomyelination syndrome 0 trials
-
Acquired ataxia 0 trials · 1 incl. sub-types
2 sub-types
-
Sensory ataxia 0 trials
2 sub-types
- Autosomal dominant sensory ataxia 1 0 trials
- Vestibular ataxia 0 trials
Most studied deeper sub-types
-
Experimental Friedreich's ataxia drug tested in kids – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…
Phase 1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Virus therapy fails to advance in colorectal cancer trial
Disease control Stopped earlyThis study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…
Phase 2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC